• Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery
  • Global ondansetron market projected to reach $2.98 billion by 2034, up from $1.82 billion in 2025, according to DataIntelo
  • Commercial rollout supported by Nora Pharma's established Canadian distribution network, further expanding Sunshine Biopharma's generic prescription drug portfolio

FORT LAUDERDALE, FL / ACCESS Newswire / September 24, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the areas of oncology and antivirals, is pleased to announce that it has launched generic Ondansetron tablets of 4mg and 8mg in the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.

Ondansetron is widely prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering two strengths (4mg and 8mg) and film-coated tablets, healthcare providers can better tailor the treatment to individual patient needs and physical condition.

According to DataIntelo, the global Ondansetron market was valued at $1.82 billion in 2025 and is projected to reach $2.98 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.6%. The rapid growth is driven by escalating cancer diagnoses worldwide, increased number of surgical procedures, and broad-based adoption of Ondansetron across multiple clinical indications. The global Nausea Medicine Market is growing steadily, fueled by increasing cases of nausea related to chemotherapy, motion sickness, gastrointestinal issues, and pregnancy. According to IQVIA Pharmafocus 2028, the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide.

Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Ondansetron to our portfolio of drugs represents a strategic expansion for the Company into the area of nausea and vomiting caused by cancer therapy.